Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The tail end of May 2026 saw a surge in endocrinology news, between major trial results and groundbreaking decisions from the 

. Between inhaled insulin’s approval for pediatric patients with 

 and topline data from SYNCHRONIZE-1 and TRIUMPH-1, the last 30 days have seen significant shifts all across endocrinology.

 has collected 7 of the most impactful headlines in endocrinology from last month. Catch up on any major news you may have missed below:


FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes


On May 29, 2026, the FDA approved MannKind’s inhaled insulin, Afrezza, for pediatric patients aged between 4 and 17 years with T1D or T2D. The decision came in response to positive endpoint data from the INHALE-1 study – despite failing to achieve its primary noninferiority endpoint of HbA1c reduction, the trial did demonstrate the safety of Afrezza among pediatric patients. This, taken in conjunction with existing safety data from adult trials, led to the FDA’s approval of the new indication.


FDA Grants Priority Review to Finerenone for Type 1 Diabetes and CKD


On May 21, 2026, the FDA accepted a supplemental New Drug Application for finerenone, which could expand its indication to adults with T1D and 

. The administration also granted Bayer’s supplemental application Priority Review, based in large part on results from the FINE-ONE phase 3 trial, in which patients treated with finerenone saw significantly reduced urine albumin-to-creatinine ratio (UACR) compared with placebo after 6 months.


FDA Clears EndoTool IV Cloud for Inpatient IV Insulin Dosing Support


On May 14, 2026, the EndoTool IV Cloud, a cloud-based version of Glooko’s intravenous insulin dosing decision-support platform, received FDA clearance via the 510(k) pathway. Designed to assess individualized insulin doses among hospitalized patients to support clinicians during inpatient care, the device is expected to launch commercially in the US before the end of 2026.


Crinecerfont Maintains Improvements in Pediatric CAH at 2 Years, With Patricia Fechner, MD


Patients with congenital adrenal hyperplasia (CAH) who received crinecerfont demonstrated substantially lower glucocorticoid doses and reduced symptoms compared to those receiving placebo, according to 2-year data from the CAHtalyst Pediatric study. In an interview with 

, Patricia Fechner, MD, attending physician at Seattle Children’s Hospital and a professor of pediatrics at the University of Washington School of Medicine, discusses the implications of this study for a condition often limited by the risks of glucocorticoid treatment.


SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo


Boehringer Ingelheim released topline results from the phase 3 SYNCHRONIZE-1 trial in May 2026 highlighting survodutide’s substantial weight loss outcomes in patients with 

 and overweight without T2D. The investigational glucagon-GLP-1 receptor dual agonist has already received Fast Track designation in May of 2021 and Breakthrough therapy designation in September of 2024. In an interview with 

, Carel le Roux, PhD, MSC, director of the Metabolic Medicine Group at the University College of Dublin School of Medicine and global coordinating investigator of the study, highlights the weight loss dependent benefits of survodutide and the possibility of weight loss independent benefits upon further research.


Retatrutide Meets Weight Loss Endpoints in Phase 3 Obesity Trial


Retatrutide, Eli Lilly’s investigative triple GLP-1/GIP/glucagon agonist, demonstrated substantial weight reduction among patients with overweight or obesity and ≥1 weight-related comorbidity, according to topline data from the TRIUMPH-1 trial. A total of 2339 participants were randomly assigned to 1 of 4 separate doses of retatrutide, all of which demonstrated body weight reductions >15%, versus 2.2% with placebo. Full data from the study will be presented at the American Diabetes Association (ADA) Scientific Sessions 2026 in June.


Diabetes Dialogue: ADA Scientific Sessions 2026 Preview


In this special in-studio episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the trials, presentations, and discussions they’re looking forward to at ADA 2026. Isaacs and Bellini highlight the myriad GLP-1 RA therapies expected to dominate the conference, as well as pointing out new insulin titration tools driven by continuous glucose monitor (CGM) such as Dexcom’s Smart Basal feature. The hosts express their excitement for the variety of updates to be presented at the conference in June.

Articles

Late May 2026 brought multiple regulatory and clinical inflection points in endocrinology. The FDA expanded Afrezza to children and adolescents with type 1 or type 2 diabetes, advanced finerenone toward a potential type 1 diabetes CKD indication via Priority Review, and cleared a cloud-based inpatient IV insulin decision-support tool. New data highlighted disease-modifying potential in congenital adrenal hyperplasia with crinecerfont and robust anti-obesity efficacy with next-generation incretin agonists survodutide and retatrutide. Attention now shifts to ADA 2026 updates on GLP-1–centric pipelines and CGM-enabled titration.

Catch up on major trial results, key FDA decisions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

FDA News

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Type 1 Diabetes

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Videos

7 Endocrinology Headlines You Missed in May 2026

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

https://www.hcplive.com/clinical/fda-news

May 2026 brought significant developments across 

, from regulatory milestones to advances in precision medicine and disease management.

These developments were highlighted by the 

 (FDA)'s Priority Review of finerenone (Kerendia) for adults with type 1 diabetes and 

, signaling a potential expansion of treatment options for a high-risk population. Precision medicine also took center stage, with investigators demonstrating that a novel 9-protein plasma risk score could identify APOL1 high-risk individuals most likely to progress to kidney failure years before traditional markers such as eGFR decline or albuminuria emerge. Meanwhile, growing attention to APOL1-mediated kidney disease (AMKD) and

reflected an ongoing shift toward mechanism-based care, with experts emphasizing earlier diagnosis, targeted therapeutic strategies, genetic risk assessment, and evolving definitions of disease remission.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

On May 21, 2026, Bayer announced the FDA had accepted a supplemental New Drug Application (sNDA) and granted Priority Review for finerenone (Kerendia) in adults with type 1 diabetes and chronic kidney disease (CKD), based on positive results from the phase 3 FINE-ONE trial.

9-Protein Plasma Score Predicts Kidney Failure Risk in APOL1 High-Risk Individuals Before Visible CKD

A plasma proteomic risk score composed of 9 circulating proteins identified APOL1 high-risk individuals most likely to progress to kidney failure years before conventional clinical markers, including estimated glomerular filtration rate (eGFR) decline and albuminuria, became apparent.

Derived from the Penn Medicine BioBank and validated in 2 independent cohorts, the score could help address a longstanding challenge in nephrology: determining which APOL1 carriers are most likely to develop progressive kidney disease.

IgAN Enters “Mechanism-First Era” Reframing Diagnosis, Treatment, and Remission

In recognition of IgAN Awareness Day on May 14, 2026, HCPLive spoke with leading nephrologists about the evolving management of IgAN, including earlier diagnosis, treatment sequencing strategies, biomarker development, and the changing definition of remission.

APOL1-Mediated Kidney Disease: From Genetic Discovery to the Edge of Precision Medicine

As targeted therapies move closer to clinical practice, experts highlighted ongoing challenges in AMKD, including delayed diagnosis, variable disease progression, and disparities in access to genetic testing and specialized care. For AMKD Awareness Day, HCPLive spoke with 5 experts about the field's evolution from genetic discovery to emerging precision treatment approaches.

May 2026 saw nephrology advance on multiple fronts, spanning regulation, proteomics, and mechanism-driven care. The FDA granted Priority Review to expand finerenone use to adults with type 1 diabetes and CKD following phase 3 FINE-ONE data. A 9-protein plasma risk score, derived from the Penn Medicine BioBank and validated in two cohorts, stratified APOL1 high-risk individuals years before eGFR decline or albuminuria. IgA nephropathy and APOL1-mediated kidney disease discussions emphasized earlier diagnosis, biomarker-guided sequencing, genetic testing, and evolving, clinically meaningful remission endpoints.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Chronic Kidney Disease

4 Nephrology Headlines You Missed in May 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 editorial team highlighted many different developments across the 

 landscape, including recent clinical trial findings, emerging therapeutic targets, and evolving perspectives on patient care and physician practice. News coverage spanned inflammatory skin diseases including atopic dermatitis, psoriasis, and nummular eczema, while also examining broader issues in 2 notable feature pieces.

Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD

Phase 3 LumiNE Trial to Assess Lebrikizumab in Nummular Eczema, With Kilian Eyerich, MD, PhD

How Online Informed Patients Are Changing Dermatology Visits

OX40 Targeting in Atopic Dermatitis: A Pathway Under Scrutiny

ADMIRE: Upadacitinib Efficacious in Atopic Dermatitis with Prurigo Nodules

Skin of Color Savvy: The Sunscreen Gap—Cancer Prevention in Skin of Color

The Medical Sisterhood: The Hidden Cost of Being the Compassionate Doctor, With Lisa Swanson, MD

 reported on promising investigational and approved therapies, including novel combination approaches for psoriasis and overweight, the assessment of lebrikizumab in nummular eczema, and new data supporting upadacitinib in those living with atopic dermatitis and prurigo nodules. Coverage also included 2 podcasts from the 

 series, with prominent guests highlighting evolving issues in the space.

In the following summary of May 2026 dermatology headlines, updates reflect continued innovation in inflammatory skin disease management, growing attention to health equity and patient engagement, and ongoing conversations related to the future of dermatology:

What Were Some Notable Dermatology Headlines from May 2026?

Mark Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai, spoke with 

 in a May interview regarding his team’s phase 3b TOGETHER-PsO analysis findings indicating the combination of ixekizumab (Taltz) with tirzepatide (Zepbound) may significantly improve outcomes for those living with moderate-to-severe plaque psoriasis and obesity or overweight.
He spoke about this 52-week, randomized phase 3b study, highlighting the impact of ixekizumab alone versus ixekizumab combined with tirzepatide, with the investigators having assessed 274 adults with psoriasis and obesity or overweight.

In another May story, Kilian Eyerich, MD, PhD, chair and professor at the Department of Dermatology and Venerology of the University of Freiburg, Germany, and guest professor at the Karolinska Institute in Stockholm, Sweden, spoke in an interview with the team about his team’s recently launched study. This followed Almirall’s announcement of the phase 3 clinical trial assessing lebrikizumab in those with nummular eczema. Eyerich spoke about the study’s significance for this disease state, noting researchers believe atopic dermatitis and nummular eczema may share overlapping inflammatory pathways involving interleukin (IL)-13.

In the ADMIRE study, approximately two-thirds of patients with moderate-to-severe atopic dermatitis and prurigo nodules (AD-PN) saw significant itch reduction within 12 weeks of initiating upadacitinib in real-world clinical settings, data released in May suggest. The ADMIRE analysis prospectively followed 120 Japanese individuals with moderate-to-severe atopic dermatitis with prurigo nodules for 48 weeks after using upadacitinib in routine practice. This analysis was led by investigators such as Hiroyuki Murota, MD, PhD, from the Nagasaki University Graduate School of Biomedical Sciences’ Department of Dermatology.

What Were Some Notable Dermatology Feature Articles in May?

This feature highlights the recent development of the “online-informed” patient, with this trend transforming visits to dermatology practices in a variety of ways. The feature points to clinicians increasingly dealing with patients who greet them armed with Reddit-informed treatment data, TikTok skincare advice, AI-generated differential diagnoses, and screenshots from conversations with ChatGPT or Claude. This feature includes interviews with 4 leaders in dermatology, pointing to online information spread in dermatology as a trend that is simultaneously empowering and potentially hazardous.

This feature touches on atopic dermatitis, a heterogeneous inflammatory skin disease driven by immune dysregulation across multiple T cell axes. The feature notes the considerable variation in the disease’s clinical presentation by patients’ race, age, and comorbidity profile. Within the current therapeutic framework, available drugs target these pathways by blocking individual cytokines such as IL-4, IL-13, or IL-31, or interrupting intracellular JAK-STAT signaling. However, there have been 2 agents targeting the OX40 pathway, an upstream regulator of T cell activation operating at the interface between antigen-presenting cells and T cells, that recently advanced into late-phase clinical development in atopic dermatitis.

Which Dermatology Podcasts Posted Episodes in May 2026?

 podcast was centered on “the sunscreen gap” in skin cancer prevention among individuals with skin of color. The episode featured a conversation between experts highlighting issues such as delayed diagnoses, persistent misconceptions among such populations, and systemic barriers contributing to diminished outcomes despite lower overall incidence rates of skin cancer in skin of color populations. Host Rebecca Vasquez, MD, of UT Southwestern Medical Center, spoke alongside Jeanine Downie, MD, founder of image Dermatology PC in Montclair, New Jersey; Henry Lim, MD, former chair of dermatology at Henry Ford Health; and Jane Yoo, MD, assistant clinical professor at the Icahn School of Medicine at Mount Sinai.

The Medical Sisterhood: The Hidden Cost of Being the Compassionate Doctor, With Lisa Swanson MD

 podcast featured a discussion between host Mona Shahriari, MD, associate clinical professor of dermatology at Yale University and practicing dermatologist in Connecticut, and Lisa Swanson, MD, a dual board-certified dermatologist and pediatric dermatologist at Ada West Dermatology and St. Luke’s Children’s Hospital in Boise, Idaho. The pair of speakers held a discussion regarding a variety of topics such as physician identity, representation, emotional labor, and the unique interpersonal dynamics surrounding pediatric dermatology.

May 2026 dermatology updates emphasized innovation in inflammatory skin disease management, alongside practice-facing shifts and equity discussions. Phase 3b TOGETHER-PsO data suggested ixekizumab plus tirzepatide may improve outcomes in moderate-to-severe plaque psoriasis with obesity/overweight. A phase 3 LumiNE program launched to evaluate IL-13 blockade with lebrikizumab in nummular eczema, reflecting potential mechanistic overlap with atopic dermatitis. Real-world ADMIRE findings supported upadacitinib for atopic dermatitis with prurigo nodules. Features examined online-informed patient dynamics and OX40-pathway targeting, complemented by podcasts on sunscreen inequities and physician emotional labor.

This installment of our Month in Review series highlights top news headlines and podcast updates in dermatology from May 2026.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

7 Dermatology Headlines You Missed in May 2026

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Johnson & Johnson announced nipocalimab met the primary endpoint of the Phase 2 JASMINE trial, significantly reducing disease activity in adults with 

moderate-to-severe systemic lupus erythematosus (SLE)

 through Week 52, according to a press release issued on June 3, 2026.

Nipocalimab is the first neonatal Fc receptor (FcRn) blocker investigated in SLE and represents a mechanistically distinct approach from approved agents. Results were presented as a late-breaking abstract at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London.

What is nipocalimab being studied for in SLE?

Nipocalimab is an investigational FcRn blocker being evaluated for the treatment of moderate-to-severe SLE in adults. It is not FDA-approved for this indication; a phase 3 study is currently recruiting.

Nipocalimab selectively blocks the neonatal Fc receptor (FcRn), reducing circulating pathogenic IgG autoantibodies and immune complexes implicated in SLE-associated inflammation, while preserving broader immune function.

JASMINE met its primary endpoint: nipocalimab 15 mg/kg achieved an SRI-4 response rate of 53.5% versus 46.7% for placebo at week 24, with responses sustained through week 52 and amplified in autoantibody-positive participants.

"The consistent improvements observed across established disease activity measures and reductions in pathogenic immunoglobulin G autoantibodies are encouraging and support the continued investigation of nipocalimab as a targeted treatment approach for people living with systemic lupus erythematosus," Richard Furie, MD, Chief of the Division of Rheumatology at Northwell, said in a statement. "These 52-week findings support the potential of nipocalimab to provide disease control over time for a broad population of autoantibody-positive adult patients living with moderate-to-severe systemic lupus erythematosus, a disease in which many patients experience ongoing disease activity and risk of irreversible organ damage."

Existing approved therapies for SLE, including belimumab and anifrolumab, target B-cell survival or type I interferon signaling, respectively. The JASMINE results provide the first proof-of-concept data for FcRn blockade in this indication, adding to a mechanism already under late-phase investigation in conditions including generalized myasthenia gravis and warm autoimmune hemolytic anemia.

JASMINE was a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study enrolling 228 adults aged 18 to 65 years with active, moderate-to-severe SLE.

Eligible participants were positive for antinuclear antibodies (ANA), anti-double-stranded DNA (anti-dsDNA), and/or anti-Smith antibodies and had not responded to at least one standard-of-care treatment. Participants were randomly assigned in a 1:1:1 ratio to intravenous nipocalimab 5 mg/kg, nipocalimab 15 mg/kg, or placebo every 2 weeks through week 52, each administered alongside protocol-permitted background medications.

The primary endpoint was the SLE Responder Index-4 (SRI-4) composite response at week 24. The SRI-4 integrates criteria from the SELENA-SLEDAI, Physician Global Assessment, and BILAG-2004 indices. 

At week 24, nipocalimab 15 mg/kg achieved an SRI-4 response rate of 53.5% compared with 46.7% for placebo plus background medication, meeting the primary endpoint.

Results showed benefit was maintained at the key secondary endpoint of SRI-4 at week 52, where 53.6% of participants receiving nipocalimab 15 mg/kg achieved a response compared with 39.7% in the placebo group.

Nipocalimab 15 mg/kg also demonstrated greater achievement of Lupus Low Disease Activity State (LLDAS), a key exploratory endpoint supporting a treat-to-target approach, compared with placebo at week 52 (37.5% vs 20.5%). LLDAS achievement requires low disease activity on validated composite measures, a prednisolone dose no greater than 7.5 mg daily, and well-tolerated immunosuppressive therapy.

A predefined autoantibody-positive subgroup, which represented approximately 80% of the enrolled population, showed magnified treatment separation at week 52. SRI-4 response rates in this subgroup were 58.2% vs 36.1% and LLDAS achievement was 38.9% vs 18.0% for nipocalimab 15 mg/kg versus placebo, respectively.

The safety profile of nipocalimab was consistent with prior studies of the agent and no new signals were identified. The most common adverse reactions occurring in ≥ 10% of nipocalimab-treated participants were nasopharyngitis, headache, urinary tract infection, and nausea.

“The JASMINE results provide important new insights into the potential of nipocalimab for adults with moderate-to-severe systemic lupus erythematosus as we continue advancing this program,” Leonard Dragone, MD, PhD, Disease Area Leader, Autoantibody and Rheumatology, Johnson & Johnson, said in a statement. “We are especially encouraged by the responses observed in autoantibody-positive study participants. These findings support the potential of nipocalimab as a targeted, immunoselective treatment designed to address underlying drivers of systemic lupus erythematosus.”

Nipocalimab received FDA Fast Track designation in SLE in January 2026. The ongoing Phase 3 GARDENIA study is currently enrolling adults with SLE. Nipocalimab is also under investigation in rheumatoid arthritis, Sjögren's disease, generalized myasthenia gravis, warm autoimmune hemolytic anemia, and fetal/neonatal alloimmune conditions.

Johnson & Johnson. Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study. Published June 3, 2026. Accessed June 3, 2026. https://www.jnj.com/media-center/press-releases/johnson-johnson-late-breaking-results-show-nipocalimab-significantly-reduced-systemic-lupus-erythematosus-sle-disease-activity-in-a-phase-2-study 

ClinicalTrials.gov. NCT07438496 (GARDENIA). Available at: https://clinicaltrials.gov/study/NCT07438496. Accessed June 3, 2026.

Johnson & Johnson reported Phase 2 JASMINE data showing the FcRn blocker nipocalimab reduced disease activity in adults with moderate-to-severe SLE through 52 weeks. In this multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial (n=228), IV nipocalimab 15 mg/kg every 2 weeks met the primary endpoint (SRI-4 at week 24) and maintained separation at week 52. LLDAS achievement favored active treatment, with amplified benefit in an autoantibody-positive subgroup (~80%). Safety was consistent with prior experience; Phase 3 enrollment is ongoing.

Phase 2 JASMINE data show nipocalimab achieved SRI-4 response rates of 53.5% vs 46.7% with placebo at week 24, with benefits sustained through week 52.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Michael J. Payette, MD
Credit: Middlesex Health

The Genital Psoriasis Wellness Consortium has published expert consensus offering age-specific guidance for 

 care, spanning physical examination, pediatric and adolescent treatment, and adult and geriatric treatment. 

The recommendations, which are published in the 

, are part of a second-phase initiative developed by a 13-member US-based multidisciplinary panel. 

Genital involvement occurs in more than 60% of patients with psoriasis over the disease course, yet it remains under-recognized and undertreated. No specific ICD-10-CM code exists for the condition, limiting data capture and obscuring its true burden. The panel built on the Consortium's earlier consensus work to address persistent gaps in diagnosis, communication, and age-appropriate management.

“Genital psoriasis is one of the most impactful, yet consistently overlooked, manifestations of psoriatic disease. Although it will affect the majority of individuals with psoriasis at some point in their lives, genital psoriasis remains vastly under diagnosed because clinicians aren't routinely asking and patients are hesitant to bring it up due to its sensitive nature,” said Michael J. Payette, MD, MBA, dermatologist at Central Connecticut Dermatology, associate clinical professor at UConn Health, Genital Psoriasis Consortium member, and manuscript lead author. “Our consensus work represents a 'call to action' and an important step forward, giving clinicians a comprehensive, age-specific roadmap to approach genital psoriasis with the same rigor they bring to every other aspect of dermatologic care. It has the potential to meaningfully direct the course of outcomes for individuals with genital psoriasis who have gone either undiagnosed or untreated for far too long.”

What did the Genital Psoriasis Wellness Consortium consensus recommend?

The panel recommended routine genital assessment within full-body skin exams, empathetic stigma-reducing communication, and age-specific treatment, with minimized long-term topical corticosteroid use across all age groups.

How was the genital psoriasis consensus developed?

A 13-member US-based multidisciplinary panel used a modified Delphi process with a systematic literature review, defining consensus as at least 75% agreement on a seven-point Likert scale.

Which topical is FDA approved for genital psoriasis?

Roflumilast, a topical PDE4 inhibitor, is the only FDA-approved topical for psoriasis involving intertriginous areas, which include the genital region.

The panel applied a modified Delphi process with the nominal group technique, informed by a systematic PubMed literature review conducted in November 2024. Three subcommittees addressed physical exam and diagnosis, pediatric and adolescent treatment, and adult and geriatric treatment. Two rounds of anonymous online feedback refined each statement, with consensus defined as at least 75% agreement, using scores of 5 or higher on a 7-point Likert scale.

All statements reached consensus. The panel positioned routine genital assessment within comprehensive full-body skin examinations at both initial and follow-up visits. Verbal consent before the exam, ideally before the patient disrobes, was endorsed as a minimum standard, alongside the offer of a chaperone or third-party presence consistent with institutional and state requirements.

Panelists also recommended a structured differential framework organized by lesion morphology, lesion depth, and etiologic category. The approach aims to distinguish genital psoriasis from mimics such as lichen planus, candidiasis, and contact dermatitis, reducing misdiagnosis in a sensitive anatomical region.

Age-specific treatment guidance and corticosteroid stewardship

For pediatric and adolescent patients, the panel endorsed access to the full spectrum of therapies through shared decision making among clinicians, caregivers, and patients. Members favored simple regimens, gamified adherence tools, and in-office topical samples to support comfort and follow-through. When injectable agents are appropriate, the panel suggested selecting options with the fewest annual injections within a comparable class.

In adults and older adults, the panel advised basing treatment on comorbidities, polypharmacy, and individual goals rather than age alone. Skin fragility and higher irritation susceptibility in older patients warrant therapies with established safety in intertriginous areas.

Across every age group, panelists prioritized minimizing long-term topical corticosteroid use, citing risks of skin atrophy, striae, and systemic absorption with prolonged exposure. They highlighted advanced targeted topicals as alternatives to corticosteroids.

These include roflumilast (Zoryve), a topical phosphodiesterase-4 [PDE4] inhibitor, the only FDA-approved topical for psoriasis in intertriginous areas, and tapinarof (Vtama), an aryl hydrocarbon receptor [AhR] inhibitor, with pediatric tapinarof studies underway.

 Access barriers such as insurance denials and prior authorization were flagged as threats to adherence.

To reduce stigma, the panel offered sample language for clinicians introducing a genital exam: “We know some patients may find this uncomfortable; a routine full skin exam includes the genitals.” The framing positions genital assessment as a normal component of comprehensive skin examination rather than an exception.

The work extends the Consortium's first-phase consensus, published in 2025 in the Journal of the European Academy of Dermatology and Venereology Clinical Practice.

 The recommendations are positioned as a living framework, with revisions anticipated as genital-specific evidence accumulates.

Payette M, Bhutani T, Young M, et al. Considerations for genital psoriasis care across age groups: a modified Delphi consensus initiative from the Genital Psoriasis Wellness Consortium. 

. Published online May 13, 2026. doi:10.1007/s40257-026-01035-0

Arcutis Biotherapeutics. New expert consensus provides age-specific guidance for improving genital psoriasis care. Published May 2026. Accessed June 3, 2026. 

https://investors.arcutis.com/news-releases/news-release-details/new-expert-consensus-provides-age-specific-guidance-improving

Expert consensus from a US multidisciplinary panel provides age-stratified guidance to improve recognition, diagnosis, communication, and management of genital psoriasis, a common but under-assessed manifestation lacking a dedicated ICD-10-CM code. Using a modified Delphi process, the group endorsed routine genital assessment within full-body exams with explicit verbal consent and chaperone options. A structured differential by morphology, depth, and etiology was recommended to reduce misdiagnosis. Treatment emphasizes shared decision making, simplified adherence strategies, comorbidity-aware selection, and corticosteroid stewardship with targeted topicals.

The Genital Psoriasis Wellness Consortium reached consensus on age-specific recommendations on screening, care, and special populations. 

Expert Consensus Offers Age-Specific Guidance for Genital Psoriasis Care

Alan D. Betensley, MD, is a board-certified pulmonologist and associate professor at the Feinberg School of Medicine in Northwestern Medicine.

Data suggest long-term extracorporeal photopheresis may reduce mortality risk in patients with chronic lung allograft dysfunction unresponsive to standard immunosuppression.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

ECP Linked to Improved Survival in Refractory Bronchiolitis Obliterans Syndrome

May 2026 saw substantial FDA decisions, major trial results, guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Atherosclerotic Cardiovascular Disease

10 Cardiology Headlines You Missed in May 2026

Delphine Kerob, MD, is the La Roche-Posay International Scientific Director and a dermatologist for Saint Louis hospital in Paris.

Delphine Kerob, MD, in this segment of her interview, expanded on the clinical implications of new data on atopic dermatitis and lifelong impacts.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

What Are the Lasting Consequences of Childhood-Onset Atopic Dermatitis?

Marcus Shaker, MD, a professor of pediatrics and medicine at the Dartmouth Geisel School of Medicine

Screenshot 2025-11-06 at 10.12.42 AM.png

At EAC 2026, Dartmouth Children's Health allergist Marcus Shaker, MD, outlined a framework built on shared decision-making for families navigating food allergy in infancy.

Food Allergy

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Early Introduction, Rescue Refeeding, and Home OIT: Reframing Pediatric Food Allergy Management

View the top 6 trials to watch ahead of a star-studded ADA 2026.

ADA Scientific Sessions 2026 Preview: 6 Trials to Know

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Lorundrostat Lowers BP, Albuminuria in Phase 3 CKD Hypertension Analysis

A study revealed adults with childhood onset atopic dermatitis may see greater limitations in career and educational options.

Latest News

7 Endocrinology Headlines You Missed in May 2026

4 Nephrology Headlines You Missed in May 2026

7 Dermatology Headlines You Missed in May 2026

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Expert Consensus Offers Age-Specific Guidance for Genital Psoriasis Care